CA 19-9 Concentration in Peripheral and Portal Blood of Patients Operated on for Pancreatic Tumor

• Authors: Krzysztof Szwedziak , Janusz Strzelczyk
• Languages of publication: EN

Abstracts

EN

Pancreatic cancer is one of the most common malignant diseases in the world. Morbidity rate increases and now reaches around 200 000 new cases yearly. Poor prognosis mainly results from usually late diagnosis and non-specific symptoms. Despite of advances in radiological diagnosis of pancreatic diseases, differentiation between malignant and inflammatory pancreatic tumors still remains difficult. The aim of the studywas the assessment of clinical utility of CA 19-9 in peripheral and portal blood of patients with pancreatic tumor. Material and methods.66 patients were hospitalized at the Department of General and Transplant Surgery between October 2010 nad July 2012 due to pancreatic tumor. Blood samples were collected from peripheral vein before surgery and intraoperatively from the portal vein to measure CA 19-9 concentration. 57 patients were diagnosed with malignant tumor and 9 with inflammatory lesion. Metastases to the liver were present in 7 of all patients. Radical surgery (Whipple’s procedure in 27 cases) were performed in 34 patients. Results.Significantly higher CA 19-9 concentration in the peripheral blood and in the portal blood as well was found in the pancreatic cancer group than in the inflammatory lesions group (51.2 vs <3 and 52.1 vs 6.3 respectively). Marker concentration in case of malignant lesions was significantly higher in the portal blood than in the peripheral blood (52.1 vs 51.2; p<0.05). CA 19-9 concentration of patients with malignant pancreatic tumors but without metastases to the liver was significanlty higher in the portal blood than in the peripheral blood (19.32 vs 18.65; p<0.01). Conclusions.Determination of the CA 19-9 concentration not only in the peripheral blood but in the portal blood as well might be a useful diagnostic tool in order to differentiate between the malignant and inflammatory pancreatic tumors. We did not see any statistically significant dependency between the CA 19-9 concentrations in the peripheral blood and portal blood and if the surgery was radical or not, but significantly higher concentrations of CA 19-9 in the portal blood than the peripheral blood among the patients suffering from the malignant pancreatic tumor without metastases to the liver might be useful tool when decisions on performing pancreatoduodenectomy are being made since this surgery is forborne from when metastases are present.

Keywords

EN

pancreatic cancer   CA 19-9   portal blood  

• Publisher: De Gruyter Open
• Journal: Polish Journal of Surgery
• Year: 2013
• Volume: 85
• Issue: 1
• Pages: 20-28

Dates

published

1 - 01 - 2013

online

16 - 03 - 2013

References

• 1. Celiński K, Mądro A: Postępy w diagnostyce i leczeniu raka trzustki. Gastroenterol Pol 2005; 12: 341-46
• 2. Krejs GJ: Pancreatic cancer: epidemiology and risk factors. Dig Dis 2010; 28: 355-58.[PubMed][WoS][Crossref]
• 3. Ballehaninna UK , Chamberlain RS: The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 2012; 3: 105-19.
• 4. Delbeke D, Pinson CW : Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg 2004; 11: 4-10.[Crossref]
• 5. Magee CJ, Ghanch P, Neoptolemos JP: Surgical and medical therapy for pancreatic carcinoma. Best Pract Res Clin Gastroenterol 2002; 16: 435-55.[PubMed][Crossref]
• 6. Mackie CR , Cooper MJ, Lewis MH , Moossa AR : Nonoperative differentiation between pancreatic cancer and chronic pancreatitis. Ann Surg 1979; 189: 480-87.
• 7. Van Gulik TM , Reeders JW, Bosma A et al.: Incidence and clinical findings of benign, inflammatory disease in patients resected for presumed pancreatic head cancer. Gastrointest Endosc 1997; 46: 417-23.[Crossref][PubMed]
• 8. Fleisher M, Sturgeon CM , Lamerz R, Witliff JL: Tumor markers: Physiology, Pathobiology, Technology and Clinical Applications. Chicago: AACC press; 2002.
• 9. Koprowski H, Steplewski Z, Mitchell K et al.: Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957-71. [Crossref][PubMed]
• 10 . Steinberg W: The clinical utility of the CA 19-9 tumor associate antigen. Am J Gastroenterol 1990; 85: 350-55.
• 11 . Goonnetilleke KS, Siriwardena AK : Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007; 33: 266-70. [WoS][Crossref]
• 12 . Hotakainen K, Tanner P, Alfthan H et al.: Comparison of three immunoassays for CA 19-9. ClinChim Acta 2009; 400: 23-27.
• 13 . Sperti C, Pasquali C, Catalini S et al.: CA 19-9 as a prognostic index after resection for pancreatic cancer. J Surg Oncol 1993; 52: 137-41. [Crossref]
• 14 . Safi F, Schlosser W, Falkenreck S, Beger HG: Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology 1998; 45: 253-59.
• 15 . Duffy MJ, Sturgeon C, Lamerz R et al.: Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. AnnOncol 2010; 21: 441-47.
• 16 . Tessler DA , Catanzaro A, Velanovich V et al.: Predictors of cancer in patients with suspected pancreatic malignancy without a tissue diagnosis. Am J Surg 2006; 191: 191-97.
• 17 . Duffy MJ: CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 1998; 35: 364-70.
• 18 . Paganuzzi M, Onetto M, Marroni P et al.: CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 1988; 61: 2100-08. [Crossref]
• 19 . Bedi MM , Gandhi MD , Jacob G et al.: CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit? IndianJ Gastroenterol 2009; 28: 24-27. [Crossref]
• 20 . Taylor B: Carcinoma of the head of the pancreas versus chronic pancreatitis: diagnostic dilemma with significant consequences. World J Surg 2003; 27: 1249-57. [PubMed][Crossref]
• 21 . Yeo TP , Lowenfels AB: Demographics and epidemiology of pancreatic cancer. Cancer J 2012; 18: 477-84. [Crossref][PubMed]
• 22 . Michaud DS: Epidemiology of pancreatic cancer. Minerva Chir 2004; 59: 99-111. [PubMed]
• 23 . Rückert F, Pilarsky C, Grützmann R: Serum Tumor Markers in Pancreatic Cancer - Recent Discoveries. Cancers 2010; 2: 1107-24. [Crossref][PubMed]
• 24 . Kim JE, Lee KT , Lee JK et al.: Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004; 19: 182-86.[Crossref]
• 25 . Brody JR, Witkiewicz AK , Yeo CJ: The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer. Adv Surg 2011; 45: 301-21. [PubMed][Crossref]
• 26 . Zhang S, Wang YM , Sun CD et al.: Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J. Gastroenterol 2008; 14: 3750-53. [WoS][Crossref]
• 27 . Kim TH , Han SS, Park SJ et al.: CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer. Int J Radiat Oncol Biol Phys 2011; 81: e743-8. [WoS][Crossref]
• 28 . Yachida S, Jones S, Bozic I et al.: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-17. [WoS]
• 29 . Disibio G, French SW: Metastatic patterns of cancers: results from a large autopsy study. ArchPathol Lab Med 2008; 132: 931-39.
• 30 . Amikura K, Kobari M, Matsuno S: The time of occurrence of liver metastasis in carcinoma of the pancreas. Int J Pancreatol 1995; 17: 139-46.[PubMed]

Identifiers

DOI

10.2478/pjs-2013-0004